From Financing to Exit: What's New for Life Sciences Companies? | McDermott

From Financing to Exit: What’s New for Life Sciences Companies?

Overview


Programme

17.00 Registration
17.30 Panel discussion
19.00 Cocktail Reception

McDermott is pleased to invite you to a panel discussion to be held in our Paris office on May 23, immediately post-BioEquity – see our panel of outside experts listed below. Also, we have selected financing/exit specialists from McDermott’s BioEquity Team to be present for informal commentary.

Introduction

Emmanuelle Trombe, Partner, McDermott Will & Emery Paris

SPEAKERS

Rafaele Tordjman, Special Advisor, Sofinnova

Cédric Moreau, Managing Director, Oddo

Glyn Edwards, Chief Executive Officer, Summit Therapeutics plc

Jacky Vonderscher, Ph.D, Chief Executive Officer, Enyo Pharma SA

Paul Hadden, Managing Director, HealthCare Royalty Partners

Mark Selinger, Partner, McDermott Will & Emery New York

Kristian Werling, Partner, McDermott Will & Emery Chicago

Dig Deeper

Boston, MA / Speaking Engagements / June 16 – 19, 2025

BIO International Convention 2025

Paris, France / Speaking Engagements / June 17, 2025

Innovative Medical Device Start Ups Day 2025 | SNITEM

Poznań, Poland / L'Université de Lorraine / May 8, 2025

The Duty of Care between National and European Union Law | Conference 2025

Dallas, TX / McDermott Event / May 1, 2025

BIO BREAK: Dallas' Monthly Life Sciences Happy Hour

Paris, France / Speaking Engagements / April 10, 2025

GACS 2025 - Global Anticorruption & Compliance Summit